Globe Newswire (Thu, 7-May 8:05 AM ET)
Globe Newswire (Wed, 6-May 8:05 AM ET)
Globe Newswire (Wed, 15-Apr 8:05 AM ET)
Globe Newswire (Mon, 6-Apr 8:05 AM ET)
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
Globe Newswire (Mon, 30-Mar 8:07 AM ET)
Globe Newswire (Wed, 11-Mar 8:05 AM ET)
Market Chameleon (Tue, 4-Nov 4:55 AM ET)
SCNX Gains Institutional Reach as Arbli Becomes First FDA-Approved Losartan Oral Suspension
Market Chameleon (Thu, 23-Oct 5:54 AM ET)
SCNX Breaks Ground with FDA-Approved Liquid Losartan, Opening $256M U.S. Market Opportunity
Market Chameleon (Thu, 16-Oct 5:56 AM ET)
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
Scienture Holdings trades on the NASDAQ stock market under the symbol SCNX.
As of May 14, 2026, SCNX stock price was flat at $0.41 with 270,853 million shares trading.
SCNX has a beta of 2.36, meaning it tends to be more sensitive to market movements. SCNX has a correlation of 0.03 to the broad based SPY ETF.
SCNX has a market cap of $16.70 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that SCNX belongs to (by Net Assets): VXF.
SCNX has underperformed the market in the last year with a return of -54.8%, while the SPY ETF gained +28.6%. In the last 3 month period, SCNX fell short of the market, returning -5.1%, while SPY returned +10.0%. However, in the most recent 2 weeks SCNX has outperformed the stock market by returning +5.1%, while SPY returned +4.1%.
SCNX support price is $.39 and resistance is $.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCNX shares will trade within this expected range on the day.
